{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:15:34Z","timestamp":1777958134140,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Imaging"],"DOI":"10.1038\/s44303-026-00168-5","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:51:25Z","timestamp":1777888285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[64Cu]Cu-DOTA-TYPE7: a targeted PET radiotracer for imaging EphA2+ tumors"],"prefix":"10.1038","volume":"4","author":[{"given":"Alexis M.","family":"Sanwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiane S.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine N.","family":"Haugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco N.","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivis F.","family":"Chaple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"168_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1568009053765780","volume":"5","author":"RC Ireton","year":"2005","unstructured":"Ireton, R. C. & Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets 5, 149\u2013157 (2005).","journal-title":"Curr. Cancer Drug Targets"},{"key":"168_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrm.2015.16","volume":"17","author":"A Kania","year":"2016","unstructured":"Kania, A. & Klein, R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat. Rev. Mol. Cell Biol. 17, 240\u2013256 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"168_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00432-010-0936-2","volume":"137","author":"Y Liu","year":"2011","unstructured":"Liu, Y. et al. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J. Cancer Res. Clin. Oncol. 137, 761\u2013769 (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"168_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/cncr.22415","volume":"109","author":"YG Lin","year":"2007","unstructured":"Lin, Y. G. et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109, 332\u2013340 (2007).","journal-title":"Cancer"},{"key":"168_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.4161\/cbt.7.7.6168","volume":"7","author":"C Lu","year":"2008","unstructured":"Lu, C. et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol. Ther. 7, 1098\u20131103 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"168_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4161\/cbt.8.3.7485","volume":"8","author":"NV Margaryan","year":"2009","unstructured":"Margaryan, N. V. et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol. Ther. 8, 279\u2013288 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"168_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ijc.10860","volume":"103","author":"T Miyazaki","year":"2003","unstructured":"Miyazaki, T., Kato, H., Fukuchi, M., Nakajima, M. & Kuwano, H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer 103, 657\u2013663 (2003).","journal-title":"Int. J. Cancer"},{"key":"168_CR8","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.21873\/anticanres.13834","volume":"39","author":"H Kurose","year":"2019","unstructured":"Kurose, H. et al. Elevated expression of EPHA2 is associated with poor prognosis after radical prostatectomy in prostate cancer. Anticancer Res 39, 6249\u20136257 (2019).","journal-title":"Anticancer Res"},{"key":"168_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/1078-0432.CCR-15-0603","volume":"22","author":"PD Dunne","year":"2016","unstructured":"Dunne, P. D. et al. EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clin. Cancer Res. 22, 230\u2013242 (2016).","journal-title":"Clin. Cancer Res."},{"key":"168_CR10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1940-6207.CAPR-09-0212","volume":"2","author":"JM Brannan","year":"2009","unstructured":"Brannan, J. M. et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev. Res. (Philos.) 2, 1039\u20131049 (2009).","journal-title":"Cancer Prev. Res. (Philos.)"},{"key":"168_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18632\/oncotarget.7931","volume":"7","author":"BA Quinn","year":"2016","unstructured":"Quinn, B. A. et al. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget 7, 13 (2016).","journal-title":"Oncotarget"},{"key":"168_CR12","doi-asserted-by":"crossref","unstructured":"Vaught, D. B. et al. EphA2 is a clinically relevant target for breast cancer bone metastatic disease. JBMR 5, e10465 (2021).","DOI":"10.1002\/jbm4.10465"},{"key":"168_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.semcdb.2011.10.014","volume":"23","author":"DM Brantley-Sieders","year":"2012","unstructured":"Brantley-Sieders, D. M. Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev. Biol. 23, 102\u2013108 (2012).","journal-title":"Semin Cell Dev. Biol."},{"key":"168_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","volume":"13","author":"T Xiao","year":"2020","unstructured":"Xiao, T. et al. Targeting EphA2 in cancer. J. Hematol. Oncol. 13, 114 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"168_CR15","doi-asserted-by":"crossref","unstructured":"Puttick, S., et al. EphA2 as a diagnostic imaging target in glioblastoma: a positron emission tomography\/magnetic resonance imaging study. Mol. Imaging. 14 7290.2015.00008 (2015).","DOI":"10.2310\/7290.2015.00008"},{"key":"168_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2967\/jnumed.115.169839","volume":"57","author":"IJG Burvenich","year":"2016","unstructured":"Burvenich, I. J. G. et al. Molecular imaging and quantitation of EphA2 expression in xenograft models with <sup>89<\/sup>Zr-DS-8895a. J. Nucl. Med. 57, 974 (2016).","journal-title":"J. Nucl. Med."},{"key":"168_CR17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-007-0503-5","volume":"34","author":"W Cai","year":"2007","unstructured":"Cai, W. et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur. J. Nucl. Med. Mol. Imaging 34, 2024\u20132036 (2007).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"168_CR18","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s00259-025-07139-9","volume":"52","author":"T Watabe","year":"2025","unstructured":"Watabe, T. et al. Theranostics using 89Zr\/177Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2). Eur. J. Nucl. Med. Mol. Imaging 52, 2887\u20132897 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"168_CR19","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.7150\/thno.96641","volume":"14","author":"M Fakiri","year":"2024","unstructured":"Fakiri, M. et al. Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide. Theranostics 14, 4701\u20134712 (2024).","journal-title":"Theranostics"},{"key":"168_CR20","doi-asserted-by":"publisher","first-page":"14623","DOI":"10.1021\/acs.jmedchem.3c01135","volume":"66","author":"Q Gan","year":"2023","unstructured":"Gan, Q. et al. Development of a 18F-labeled bicyclic peptide targeting EphA2 for molecular imaging of PSMA-negative prostate cancer. J. Med. Chem. 66, 14623\u201314632 (2023).","journal-title":"J. Med. Chem."},{"key":"168_CR21","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.2967\/jnumed.117.192245","volume":"58","author":"O Jacobson","year":"2017","unstructured":"Jacobson, O. et al. PET-guided evaluation and optimization of internalized antibody\u2013drug conjugates targeting erythropoietin-producing hepatoma A2 receptor. J. Nucl. Med. 58, 1838 (2017).","journal-title":"J. Nucl. Med."},{"key":"168_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10637-022-01237-3","volume":"40","author":"HK Gan","year":"2022","unstructured":"Gan, H. K. et al. A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. Investigat. N. Drugs 40, 747\u2013755 (2022).","journal-title":"Investigat. N. Drugs"},{"key":"168_CR23","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.7150\/thno.106948","volume":"15","author":"AK Sharma","year":"2025","unstructured":"Sharma, A. K. et al. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Theranostics 15, 4229\u20134246 (2025).","journal-title":"Theranostics"},{"key":"168_CR24","doi-asserted-by":"publisher","first-page":"e0135278","DOI":"10.1371\/journal.pone.0135278","volume":"10","author":"C Ullman","year":"2015","unstructured":"Ullman, C. et al. High affinity binders to EphA2 isolated from abdurin scaffold libraries; characterization, binding and tumor targeting. PLoS One 10, e0135278 (2015).","journal-title":"PLoS One"},{"key":"168_CR25","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.1039\/D4DT00837E","volume":"53","author":"B Qu","year":"2024","unstructured":"Qu, B. et al. 68Ga labeled EphA2-targeted cyclic peptide: a novel positron imaging tracer for triple-negative breast cancer? Dalton Trans. 53, 7946\u20137952 (2024).","journal-title":"Dalton Trans."},{"key":"168_CR26","doi-asserted-by":"publisher","first-page":"e36645","DOI":"10.7554\/eLife.36645","volume":"7","author":"DS Alves","year":"2018","unstructured":"Alves, D. S. et al. A novel pH-dependent membrane peptide that binds to EphA2 AND inhibits cell migration. Elife 7, e36645 (2018).","journal-title":"Elife"},{"key":"168_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.70010","volume":"4","author":"N Liu","year":"2025","unstructured":"Liu, N. et al. Ephrin A1 ligand-based CAR-T cells for immunotherapy of EphA2-positive cancer. MedComm Oncol. 4, e70010 (2025).","journal-title":"MedComm Oncol."},{"key":"168_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167144","volume":"433","author":"JM Westerfield","year":"2021","unstructured":"Westerfield, J. M. et al. Conformational clamping by a membrane ligand activates the EphA2 receptor. J. Mol. Biol. 433, 167144 (2021).","journal-title":"J. Mol. Biol."},{"key":"168_CR29","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1074\/jbc.REV119.009457","volume":"295","author":"JM Westerfield","year":"2020","unstructured":"Westerfield, J. M. & Barrera, F. N. Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them. J. Biol. Chem. 295, 1792\u20131814 (2020).","journal-title":"J. Biol. Chem."},{"key":"168_CR30","doi-asserted-by":"publisher","first-page":"e82861","DOI":"10.7554\/eLife.82861","volume":"12","author":"Y Ye","year":"2023","unstructured":"Ye, Y. et al. Allosteric inhibition of the T cell receptor by a designed membrane ligand. Elife 12, e82861 (2023).","journal-title":"Elife"},{"key":"168_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104914","volume":"299","author":"JA Rybak","year":"2023","unstructured":"Rybak, J. A. et al. Allosteric inhibition of the epidermal growth factor receptor through disruption of transmembrane interactions. J. Biol. Chem. 299, 104914 (2023).","journal-title":"J. Biol. Chem."},{"key":"168_CR32","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","volume":"63","author":"A Jha","year":"2022","unstructured":"Jha, A. et al. Choice is good at times: the emergence of [64Cu] Cu-DOTATATE\u2013based somatostatin receptor imaging in the era of [68Ga] Ga-DOTATATE. J. Nucl. Med. 63, 1300 (2022).","journal-title":"J. Nucl. Med."},{"key":"168_CR33","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.1039\/c3ra47302c","volume":"4","author":"K Zarschler","year":"2014","unstructured":"Zarschler, K., Kubeil, M. & Stephan, H. Establishment of two complementary in vitro assays for radiocopper complexes achieving reliable and comparable evaluation of in vivo stability. RSC Adv. 4, 10157\u201310164 (2014).","journal-title":"RSC Adv."},{"key":"168_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/ph15060728","volume":"15","author":"TT Huynh","year":"2022","unstructured":"Huynh, T. T. et al. Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer. Pharmaceuticals 15, 728 (2022).","journal-title":"Pharmaceuticals"},{"key":"168_CR35","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.3390\/molecules27175429","volume":"27","author":"C Stokke","year":"2022","unstructured":"Stokke, C., Kvassheim, M. & Blakkisrud, J. Radionuclides for targeted therapy: physical properties. Molecules 27, 5429 (2022).","journal-title":"Molecules"},{"key":"168_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/bc990167l","volume":"11","author":"LA Bass","year":"2000","unstructured":"Bass, L. A., Wang, M., Welch, M. J. & Anderson, C. J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug. Chem. 11, 527\u2013532 (2000).","journal-title":"Bioconjug. Chem."},{"key":"168_CR37","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1021\/jm030383m","volume":"47","author":"CA Boswell","year":"2004","unstructured":"Boswell, C. A. et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J. Med Chem. 47, 1465\u20131474 (2004).","journal-title":"J. Med Chem."},{"key":"168_CR38","first-page":"64","volume":"48","author":"L Wei","year":"2007","unstructured":"Wei, L. et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized \u03b1-MSH peptide analog using a cross-bridged cyclam chelator. J. Nucl. Med. 48, 64\u201372 (2007).","journal-title":"J. Nucl. Med."},{"key":"168_CR39","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","volume":"60","author":"H Akizawa","year":"2008","unstructured":"Akizawa, H., Uehara, T. & Arano, Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv. Drug Deliv. Rev. 60, 1319\u20131328 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"168_CR40","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1021\/mp500671j","volume":"12","author":"E Gourni","year":"2015","unstructured":"Gourni, E. et al. Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Mol. Pharmaceut. 12, 2781\u20132790 (2015).","journal-title":"Mol. Pharmaceut."},{"key":"168_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.7150\/thno.4295","volume":"2","author":"S Liu","year":"2012","unstructured":"Liu, S. et al. The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals. Theranostics 2, 589\u2013596 (2012).","journal-title":"Theranostics"},{"key":"168_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jlcr.3165","volume":"57","author":"Z Cai","year":"2014","unstructured":"Cai, Z. & Anderson, C. J. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J. Label. Compd. Radiopharmaceut. 57, 224\u2013230 (2014).","journal-title":"J. Label. Compd. Radiopharmaceut."},{"key":"168_CR43","doi-asserted-by":"publisher","first-page":"e28005","DOI":"10.1371\/journal.pone.0028005","volume":"6","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA. PLOS ONE 6, e28005 (2011).","journal-title":"PLOS ONE"},{"key":"168_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0969-8051(01)00203-7","volume":"28","author":"S-Y Lee","year":"2001","unstructured":"Lee, S.-Y. et al. A simple and efficient in vitro method for metabolism studies of radiotracers. Nucl. Med. Biol. 28, 391\u2013395 (2001).","journal-title":"Nucl. Med. Biol."}],"container-title":["npj Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00168-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:02:28Z","timestamp":1777957348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44303-026-00168-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1038\/s44303-026-00168-5","relation":{},"ISSN":["2948-197X"],"issn-type":[{"value":"2948-197X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}